Pediatric Antiretroviral Therapy

Human immunodeficiency virus (HIV) is one of the most serious pediatric infectious diseases, affecting around 3 million children and adolescents worldwide. Lifelong antiretroviral treatment (ART) provides multiple benefits including sustained virologic suppression, restoration and preservation of im...

Full description

Saved in:
Bibliographic Details
Published inHandbook of experimental pharmacology
Main Authors Dirajlal-Fargo, Sahera, Koay, Wei Li A, Rakhmanina, Natella
Format Journal Article
LanguageEnglish
Published Germany 01.01.2020
Subjects
HIV treatment
Antiretroviral drugs
Infants
Children
Adolescents
Online AccessGet more information

Cover

More Information
Summary:Human immunodeficiency virus (HIV) is one of the most serious pediatric infectious diseases, affecting around 3 million children and adolescents worldwide. Lifelong antiretroviral treatment (ART) provides multiple benefits including sustained virologic suppression, restoration and preservation of immune function, decreased morbidity and mortality, and improved quality of life. However, access to ART, particularly among neonates and young infants, continues to be challenging due to limited number of suitable formulations and limited access to pediatric ARV drug. Moreover, children and adolescents living with HIV may experience long-term HIV- and ART-associated comorbidities including cardiovascular, renal, neurological, and metabolic complications. We provide an overview of currently available formulations, dosing, and safety considerations for pediatric antiretroviral drugs by drug classes and according to the three age groups including neonates, children, and adolescents.
ISSN:0171-2004
DOI:10.1007/164_2019_246